newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - DENALI THERAPEUTICS INC

It's my pleasure to have the Denali team with me. To my direct right is Ryan Watts, CEO, and to his right is Katie Payne, Chief Commercial Officer, and to her right is Alex Shuth, Chief Operating Officer and Chief Financial Officer. Welcome, all of you. Great to be here. Thanks, Alexander. Yes, and please, would you mind giving us an overview of Denali, a brief overview, what you're working on, what programs you have, milestones over the next six to 12 months would be helpful to level set everything. Yeah, great. Thanks, Andrew. Great to be here in London. Great to being here with Katie and Alex. Looking forward to today's Q&A and questions. It's obviously a very exciting time at Denali over the last year, launching our first product, Avlea, for Hunter Syndrome. I think what's been most exciting about the last six months is seeing this product taken up by the community and engaging with the community and some of the, really, the case experiences with the medicine and how it's starting to transform life. And, in fact, that's our goal at Denali is to use the transport vehicle to transform life. And the way to think about it today is that we now have a product that validates the transport vehicle. That transport vehicle is the platform, and that platform can now be applied across a broader pipeline. Of a broad pipeline, in addition to Hunter Syndrome, we have Sanfilippo. So just as we talk about the future, next year we're going to be filing a BLA for San Filippo, again, enzyme transport vehicle using the technology to get across the blood-brain barrier. We also have important readouts in Pompeii and FTD granuline, I think where there's a lot of focuses in our Alzheimer's portfolio, especially with all the exciting data that continues to come out with amyloid approaches and tau approaches, including data just yesterday, for example, at CTAD. And so if you want to know about that data, just read Andrew's notes. Well done. But basically, it's a very exciting time, and the product platform pipeline is the story for us at Denali, and also a great launch by Katie and her team. So as we start to generate revenue, that extends our runway, and we're just excited to bring more products forward using the transport vehicle. Perfect. Thank you. So maybe to start with the ETV franchise, starting with Hunter and then Sanfilippo, congratulations on all the great progress. And so maybe big picture for Hunter, can you just remind us how many patients there are in both the U.S. and the ex-U.S.? What is the peak sales potential? Sure. We've been really pleased with our launch so far in the U。S. So total U.С. population is about 500 patients. And with the current FDA label, it's 375. So around 75% of the patients are eligible based on the pediatric label. And worldwide, there's about another 1,500 patients, a third outside of Europe and a third in Europe. And overall, we've had really two very successful quarters. And as Ryan mentioned, the feedback from the community has been pretty overwhelming. We had just come here from a patient event, and hearing the direct stories from the families on how well patients are doing on Avalaya really gives us that momentum going forward. And of course, our desire is to become the market leader in Hunter Syndrome, and that is defined as being able to treat all new patients. So physicians would select Avalya as the top therapy for treating new patients, as well as prevalent patients, which is the majority of patients switching from the current ERT to Avalaya and having dominant market share. And would it be fair to say, because when I think Eliprace, the existing, the other approved drug, I view your compound to be superior because it's brain penetrant, you're getting superior biomarker, and so forth. So is it fair if Eliprice is doing 700 million worldwide, give or take, you get all of that and more? Yes, yes. based on how we're seeing the trajectory of the launch today, we definitely expect that. And there's a few things that we need to achieve. One is the expansion of the label into adults. Adults make up 25% of the population, but 30% or more of the value because of their weight. Our product is weight-based dosing. And very important for us to be able to expand into the international markets. And we're doing a lot of work on the regulatory pathways. And a third of the markets that don't require our phase three COMPAS study. So that's ongoing as well. And so as long as we continue to build our base, we feel very confident that we can exceed the current standard of CARES revenues worldwide. Thanks. And one more question on the pricing side. You mentioned the weight-based dosing. Just to help frame the comparison of your price versus eloprase. What is the annual price? How does that compare to eloprice at the same dose? Great. So in the U.S., assuming a 30-kilogram patient, it's about a 60% premium. So our patients are about $800,000 versus $500,000 a year for the current ERT treatment. Great. And so the launch is going very well, even better than what I think you guys had internally expected. So it's great. You've guided Q4 to do 30 to 32 million. And I think that's two full quarters. And so come 2027, are you inclined to give more guidance either on a quarterly or annual basis? And when would be the right venue to do so? Yeah, I'll take that one. So we decided for 2026 to provide quarterly revenue guidance because we wanted to give investors the clearest picture about really how the trajectory of the launch is going we also made it very clear that the guidance would only be for 2026 and at this point we have not yet disclosed how we will approach 2027. okay very good and so katie you mentioned one other lever was the compass data to help you gain more xus approvals uh remind us when the compass state that's your confirmatory study when that data set is, and does it open up every ex-U.S. region more or less from there? Yes, so for COMPAS, I think that will open up adults for us in the U.S., but also for Europe. For the rest of the other countries, a third of the Other Countries, there are many accelerated pathways, and we can leverage the U-S CPP to be able to gain regulatory approval. Of course, that's one step in the process outside of the U.S. You need pricing and reimbursement as the second part to follow very quickly in order to gain market access into the countries. I see. And then in terms of timing, the COMPAS study will complete the two-year endpoint at the end of next year and then look to 2028 for readout. We have, of course, a sense of urgency because as we think about, as Katie mentioned, the U.S. launch and now the next third, which we're actively pursuing, and the final third, that's going to be key with Compass. And just a reminder, 65 patients, there are two cohorts. One focused on the neurologic manifestations. The other actually focused on really somatic or peripheral endpoints, and that one includes adults, so that's gonna be key. I see. And what's great is this is a head-to-head study versus alloprae. So it's a co-primary endpoint with the HS biomarker that you already have an accelar approval for. And then you're now looking at Vineland, which is, I think, the cognitive side of things. So what exactly is STAT-SIG on Vineland? Yeah, so actually, it's probably worthwhile to just comment. In these diseases, in the childhood diseases, the Vineland is a measure of behavioral endpoints. and Bailey or Kaufman, depending on age, is cognition. And so as we talk about Sanfilippo, we'll talk a little bit more about Bailey. Here we're talking about Vineland, which is, and we're actually looking at a composite where you see improvement in behavior. We see improvement at both Bailey and Vineland. That was published in the New England Journal article earlier this year, leading to, obviously, the approval. And so our assessment of how to power that study is really based on our Phase I-II experience, but also natural history data that we were able to obtain. uh including you know other studies that were large that failed but just looking at the totality of the data uh it's similar in san felipo the existence of some natural history allows us to think about the powering of these studies okay uh i well okay so well to me like ella price does not is not brain penetrant so it shouldn't do anything on violin so yeah i mean i think that the reality is that you have heterogeneity in patients so their mutations are different and their progression is different so what you're still looking for is change over time and just as a reminder in hunter syndrome most patients develop relatively normal to age two or three and then they start to fall off the developmental curve and so cohort a is focused on ages two to six which is that critical window window where you start to see a real separation okay so the hunter launch is going very well it should continue that way and then maybe switching gears to Sanfilippo, I think you have the full data set at World next year, February of 2027. Big picture, again, what's the peak sales potential of this drug? How many patients in the U.S. and ex-U.S.? So we estimate that Sanfippo is similar to Hunter, but there, for the prevalence population, it's harder to gauge exactly that number because there hasn't been any treatment. So it's an estimate, but we think the opportunity is very similar to MPS II, and yeah. And you've already shared a cut of the, is it 20 patients total cohort? I just forget, sorry, but you shared already an initial cut at the lower doses of the Sanfilippo study, and we're going to get the full data set at World, and so is it fair to assume with the full data set at World, the efficacy should look even stronger. Maybe talk about what you saw initially. You have a lot to remember, Andrew. I don't expect you to remember. So we have the first eight patients where we did essentially dose finding, both dose frequency and dose level. And what we learned was actually quite interesting. Probably we should have known this from our experience with Hunter, but more frequent dosing leads to better tolerability. And that's the case for enzyme replacement therapies. As long as you have drug on board, you can build tolerability over time. We saw 80% average reduction in CSF heparin sulfate. This is the best that's ever been shown in this disease. In addition, the ability to normalize heparine sulfate in a subset of these patients. Those that didn't normalize had more anti-drug antibodies, which again is very common in ERT therapy. So that was the first eight patients. We then enrolled an additional 12 patients. And the total data set at World will include all 20 patients.And we pre-specified with the FDA those 12 patients with their which are on the to be marketed dose including the dose escalation and that's the data that we plan to show at world which will include CSF heparin sulfate and likely other biomarkers I should have mentioned that there's a lysosomal biomarker that we showed at world this year where we had six out of seven patients normalized that was gm3 so we see a really robust biological effect and then that data set will mature over time while we also begin enrollment of the phase three study which would be the confirmatory study for the accelerated approval. I see. So 80% plus reduction on the CSF biomarker, which I think is the basis, part of the core basis for the accelerator approval. Is there a threshold? Yeah. So it's a great question. I mean, obviously, the only medicine approved on a biomarkER and MPS is Aplea. And there we achieved, you know, basically 90% reduction, so very similar robust reduction, the ability to normalize. And so we've set that bar obviously high. The real question I think you're asking is, what level of reduction do you need to drive clinical benefit? And for us, it's what comes downstream of that biomarker, which would be other lysosomal biomarkers and ultimately neurofilament light chain, which is a marker of neurodegeneration, which of course in the Hunter program, we saw over time the ability to normalize. So I think you're probably well aware that medicines that actually normalize NFL universally have received approval, and most of them are very impactful in terms of disease modification. And at World, because the initial first set of patients have been follow-up for some time now, are you tracking functional outcomes, actually, including Bailey, for instance? Yeah, so it's very early. If you actually look at the data set of the gene therapy that was approved. There's a very long-term data set. And so for us, it's early. Of course, we're tracking those. Small patient number. I think one really important point is that if you really look carefully at what's been done in San Filippo, there are categorically two types of patients. There are those that are really severe. And if you don't capture those really early, they will progress. And then there are thosethat are less severe. And DQ score is a way of measuring these things. Andso in other programs, there was essentially an intent-to-treat population that picked either very young or less severe patients. We obviously have now 20 patients, so we'll see how that data reads out. Obviously, the database lock is happening now, and the data analysis is happening now, then World will be where we present that data. I see. Okay. And then the confirmatory study you just said is starting up now, or give or take. And so unlike the Hunter confirmatory study, where it's head-to-head here, it could be open label. And so you could take a cut of the data whenever you want. So would you take a Cut? So we've just began. I mean, we have actually recently at SSIM shared the details of that phase redesign. It's actually very different than Compass, as you point out, because there's no standard of care. So all patients essentially are going to be treated with Zafi in that paradigm. And again, it's similar biomarkers, CSF heparin sulfate. Here we're looking at Bailey, obviously other endpoints, key secondary endpoints like Vinland. And we haven't guided on timing because a lot of it will be how we enroll. Obviously, the landscape is shifting as well with the approval of a gene therapy, and so we're taking that into consideration as we enroll this study. I see. So there could be maybe, are you talking to the FDA a little bit more because of Ultragenyx's approval? to help inform your design further? Right, and that's actually one of the, as I think many are aware, that approval was based on essentially looking at natural history as a comparator, which is not very commonly done. And so in some ways that bar has shifted in terms of the way we'll look at efficacy. I think it's, frankly, I think It's great for the field, especially in ultra-rare disease where it's hard to enroll these studies. And so it gives you flexibility to look at historical data sets. For us, we're comparing to baseline, which is different. We've had a lot of engagement with the FDA, so of course we're going to be looking for alignment with CDER and CBER as our program goes forward, as that bar is now different based on gene therapy. Okay. Thanks for the update on that. And so then moving on to your other programs, a whole suite of other data readouts. So maybe first with the progranulin program, I think you have a data set in first half, 2027. For FTD, remind us how big this market opportunity is. Yeah, so this program, frontotemporal dementia, our patient population are those that have a mutation in granulin, which is about 6% to 10% of the overall FTD population. The mechanism for this drug here is very similar to our mechanism in the ERT portfolio, as it is protein replacement therapy. So patients with this mutation, they lack the progranulin protein, which is a lysosomal protein, and we essentially substitute that protein. We had recently made the decision to extend the treatment duration from six months to 12 months, and this is really intended to give us the best chance of success with respect to measuring proximal and distal biomarkers. So proximal markers are those that directly measure lysosomial function, like glucosylspingosine. Distal markers, again, is neurofilament, the strongest predictor of neuronal health. As we know from our experience in the enzyme field, that neurofilament movement takes time. We had seen in our Hunter syndrome program a significant decline starting at six months and then pronounced at one year. And therefore, we extended the treatment duration. Okay, that's great. And that's very strategic. And so on NFL then, what percent reduction on NFL would make you inclined to file for accelerated approval? Yeah, that is a great question. There is not a great answer to this. I think in the end it has to be a believable reduction. Now, with respect to NFL, there is precedent and several indications. FTD is really on the spectrum of ALS and FTD, and specifically in ALS with Tofersen, there is the precedent that Toferson was approved through the accelerated approval pathway on NFL reduction, which was then a strong predictor of clinical benefit down the road. So our approach here is we will look at the totality of the data after the study reads out, and then we will then seek the conversation with the FDA about a potential accelerated approval path. And if there was no accelerated, well, as you're talking to the FDA. Do you design a confirmatory study in the meantime just to ensure you don't lose time? Yeah, it's a good question. Of course, we are scenario planning for the future, but I think step one is really to look at all the data collectively and then decide on the progress of the program. Great. So that's first half. And then shifting to your Alzheimer's programs, You have a tau, a beta program, like you said, Ryan, data sets in 2027. So maybe starting with the overall differentiation for both programs, would you mind letting us know how you're differentiating from the current therapies approved and emerging in the pipeline? Yeah, I mean, we're 25 minutes into the fireside chat, and we finally make it to Alzheimer's, which of course is one of some of our biggest programs and one of the main reasons we founded Denali is to really go after Alzheimer's disease using the transport vehicle technology. What an extraordinary time. We have now one validated target. I think with the extended, you know, all caveats considered again with the extended data set for the ASO, intrathecally delivered ASO-BIB-80, there's probably a second validated target in Alzheimer's Disease, which is really exciting. And so we set out to basically find a way to approach knocking down tau and also removing amyloid plaque using the transport vehicle. What we have is the advantage of two decades of data in front of us to be able to engineer the transport vehicles uniquely. Starting first with tau, we're using the transfer vehicle to give an even distribution throughout the brain, which is very different than intrathecal. Sorry, we give IV, we use the transport vehicule, and you get this even distribution. There we're targeting robust knockdown in CSF. what we'll assume, which we learned from Avlea, because many of you may recall that L-oprase was also delivered intrathecally. They saw reduction in biomarker, but they didn't see necessary clinical benefit, and they did not see neurofilament light chain reduced. And part of that is because there's an uneven distribution when you inject a molecule into the spine and look for even, you know, basically knockdown or uptake throughout the entire central nervous system. So here we expect when we measure CSF, we're actually measuring what's happening across the entire brain. And that'll be the key. So next year, we're looking at CSF tau and identifying the right dose once we have that dose. And obviously, on the data that we've just seen with BIV-80, I think moving forward to efficacy studies would be the way to go. In terms of A-beta, we have a uniquely engineered antibody that is essentially, I'll call it an on-off switch. So when bound to transferrin receptor, you don't engage the immune system. And as a result, you don't have an effect on reticulocytes. And hematology has been one of the challenges with the competitor molecule, as well as immunogenicity and tolerability. So I think we still see a lot of IRRs with that molecule. And our goal here is that without having the sort of amended shuttle, but rather using the transport vehicle that has the integrated TFR binding, we look for better tolerability, better hematological findings, and also that even distribution and plaque reduction. Also, I think a really key goal here is sub-Q dosing, and so that's what we imagine will be the future for these medicines. Really, a prevention setting, you have early plaque deposition, no cognitive decline, you take a sub-q dose and remove plaque safely, and that's the goal of DNL921. Oh, great. And so maybe one question on the tau, because I think the first data set is actually going to be an actual Alzheimer's patient. So what kind of tau reduction is best after the Biogen data set that we've seen? Yeah, I mean, it's a great question, and I go back to the fact that the biodistribution is quite different for intrathecal versus a BBB-enabled. But if you take at face value the tau data so far, it would be 45% or less, in fact, because you have this uneven distribution. And when you're measuring tau in the same area that you inject the ASO, probably the most tau reduction is going to be in the region where you do it. And we saw that, obviously, in Hunter syndrome, that the most reduction in heparin sulfate was in the reason where the enzyme was injected. And so I think that sets the bar probably, you know, somewhere between 20 to, you now, maybe 50 percent. And interestingly, I think there's a lot, the data is now at least what we're seeing and what you wrote about, Andrew, is the low dose is what biogen is moving forward with. So I don't know if we can use that as our own bar with the BBB technology, but it's not going to be a lot of tau reduction that's driving that clinical benefit if you also consider the uneven distribution. Right, that makes a lot sense. But also just to add one point, you're right that we are going in Alzheimer's patients first, so that's great. We went straight to Alzheimer's, multi-dose. That allows us to look at, you know, what are we seeing in terms of tau reduction, and then bringing this whole portfolio of Alzheimer's medicines forward with the transport vehicle. And for the A-beta program, my understanding is it's going to be initially in healthies, looking at reticulocytes, a precursor for anemia, but my question is actually, when do we get the MAD data in actual Alzheimer's patients? Is that a 2027 event? Yeah, so we're going back to this idea of the on-off switch for 9-2-1. The healthy volunteer allows us to assess off, meaning what does the hematology look like? If the cis-lala mutation is actually silencing the antibody when bound to transfer receptor, we know that in healthy volunteer. So that's important question number one. The on, meaning the ability to reduce plaque, will be in Alzheimer's patients. And so our goal is to have early biomarker data in 2027 for plaque reduction as well. And so it's great to be able to know, like, did you engineer the molecule the right way, which is unique from what others have done. One other comment with the transport vehicle, because you have this integrated TFR binding, all the conventional FAB approaches use these linkers. And our experience has been that after 24 hours, many of those molecules don't maintain the stability. Therefore, our brain uptake is superior. And I think importantly, probably tolerability is related to those sort of unique architectures versus an integrated TFR binding. I see. And so far for your programs, I think we're talking about the IV. You mentioned earlier you definitely want to pursue sub-Q. When exactly does that happen? Is it after these initial deals? Yeah, I'd just say stay tuned. Major focus. Major focus to have sub-q. Okay. And then I think maybe we wrap it up here then because I don't know if we have time for Pompeii, also another cast, But bottom line is you're executing, the pipeline's growing, lots of data sets coming up over the next year, and value infection period. Thank you, Andrew. Obviously, great year this year. Looking forward to lots of date next year. Thank you. Thank you . . .

Company
DENALI THERAPEUTICS INC
Keywords
DENALI THERAPEUTICS INC